Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from VRTX

How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart · Sep 2

Are Wall Street Analysts Bullish on Vertex Stock?

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

Barchart · Aug 20

What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart · Jul 13

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

MarketBeat · Jul 8

Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart · Jun 1

What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart · May 21

What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit growth in earnings.

Barchart · Apr 10

Read news from The Economist, FT, and more,
with one subscription

Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

Barchart · Feb 26

Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Barchart · Feb 17

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

Barchart · Jan 13

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Benzinga · Dec 8, 2025

Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

Barchart · Nov 18, 2025

Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Barchart · Sep 8, 2025

Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart · Aug 25, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Aug 5, 2025

Weakness In Vertex Stock Seen As Buying Opportunity

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings.

Benzinga · Aug 5, 2025

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday.

Benzinga · Aug 4, 2025

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga · Aug 4, 2025

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart · Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth.

Barchart · Jun 9, 2025

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Barchart · May 21, 2025

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

While Vertex Pharmaceuticals has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

MarketBeat · May 13, 2025

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

Barchart · Apr 23, 2025

Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect

Vertex Pharmaceuticals is set to unveil its Q1 results in the upcoming month, and analysts expect a double-digit drop in earnings.

Barchart · Mar 5, 2025

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

StockNews.com · Feb 24, 2025

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

1 2 3 4 5

Coverage From

People

William Blair

54 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Vertex Pharmaceuticals

64 stories

BMRN

31 stories

BioMarin Pharmaceutical Inc

23 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.